Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, June 9, 2025 -- For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated with improved survival and maintenance of quality of life, according to a study published online May 21 in the International Journal of Gynecological Cancer.
Dana M. Chase, M.D., from the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues randomly assigned patients with primary advanced or recurrent endometrial cancer to receive dostarlimab/placebo plus carboplatin-paclitaxel chemotherapy every three weeks for six cycles followed by dostarlimab/placebo monotherapy every six weeks for up to three years. Data were used from the first interim analysis (Sept. 28, 2022) and quality of life was assessed with the EuroQoL 5-Dimensions 5-Level questionnaire.
Overall, 241 and 246 patients in the dostarlimab and placebo arms, respectively, were analyzed for safety. The researchers found that the mean duration of quality-adjusted time without symptoms of disease progression or toxicity of treatment was significantly longer in the dostarlimab arm than the placebo arm in the overall population (24.75 versus 20.34 months). Regardless of mismatch repair/microsatellite instability status or toxicity criteria used, benefits in quality-adjusted time without symptoms of disease progression or toxicity of treatment were observed after dostarlimab treatment; benefits were mainly driven by time without symptoms of disease.
"This is the first study to demonstrate a statistically significant improvement in both overall survival and quality-adjusted survival with an immunotherapy-chemotherapy combination in this disease setting," Chase said in a statement. "It's a major step forward in the treatment of endometrial cancer."
Several authors disclosed ties to pharmaceutical companies, including GlaxoSmithKline, which manufactures dostarlimab and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Updated Guidance Improves Staging of HPV-Positive Oropharyngeal Cancer
MONDAY, July 21, 2025 -- Version nine of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control staging system (AJCC9V) human papillomavirus...
ENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer Deaths
MONDAY, July 14, 2025 -- From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the...
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 -- The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.